Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitors

This page shows the latest PCSK9 inhibitors news and features for those working in and with pharma, biotech and healthcare.

MS and cholesterol drugs picked for new UK rapid uptake push

MS and cholesterol drugs picked for new UK rapid uptake push

baby. PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia  - Cost-effective drugs that significantly lower cholesterol.

Latest news

  • CETP inhibitor class finally dies as Merck abandons anacetrapib CETP inhibitor class finally dies as Merck abandons anacetrapib

    The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have

  • Merck & Co's anacetrapib data fails to generate much excitement Merck & Co's anacetrapib data fails to generate much excitement

    contend in the statin add-on market with PCSK9 inhibitors such as Amgen's Repatha, which showed a larger (15%) risk reduction in the FOURIER trial but are still struggling to ... If Merck does choose to abandon anacetrapib the drug will follow several

  • Merck & Co's anacetrapib rescued by positive phase III trial Merck & Co's anacetrapib rescued by positive phase III trial

    cholesterol-lowering drugs now that the PCSK9 inhibitors - Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) - are being used alongside statin therapy. ... CETP inhibitors are designed to increase levels of high-density

  • Repatha outcomes data Repatha outcomes data "less than stellar"

    than stellar." Investors are now more cautious on prospects for PCSK9 inhibitors as a result, he suggested in a research note. ... It is one of only two PCSK9 inhibitors on the market, along with Sanofi and Regeneron's Praluent (alirocumab) which is also

  • Praluent can stay on market for now, says US court Praluent can stay on market for now, says US court

    Both drugs are PCSK9 inhibitors that have been approved in the US to help patients who cannot meet their cholesterol targets with existing therapy, such as statin drugs, or who have ... Praluent was approved in the US first, but Amgen has so far won the

More from news
Approximately 1 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics